{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-224147","form_type":"8-K","ticker":"FLGT","cik":"0001674930","company_name":"Fulgent Genetics, Inc.","filed_at":"2026-05-14T20:27:52+00:00","discovered_at":"2026-05-14T20:29:00.314280+00:00","generated_at":"2026-05-14T20:42:00.039043+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Fulgent Genetics shareholders approve 2026 equity plan authorizing 2M new shares","bullets":["2026 Equity Incentive Plan replaces prior 2016 plan; authorizes 2,000,000 new shares plus up to 1,500,000 from forfeited awards.","All four director nominees elected: Ming Hsieh, Linda Dong, Michael Nohaile, Regina Groves (each to serve until 2027 annual meeting).","Ratification of Deloitte & Touche LLP as independent auditor for fiscal year 2026 approved (24.5M for, 87K against).","Non-binding advisory vote on named executive officer compensation passed (19.8M for, 2.4M against, 45K abstain)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-224147","json":"https://secwatch.observer/filing/0001193125-26-224147.json","markdown":"https://secwatch.observer/filing/0001193125-26-224147.md","text":"https://secwatch.observer/filing/0001193125-26-224147.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1674930/000119312526224147/0001193125-26-224147-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1674930/000119312526224147/flgt-20260514.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T20:42:00.039043+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5e1c0bbaf5ace70c97dbdfe1a6563d99c2a61ab3","claim":"Fulgent Genetics, Inc. shareholders approved Approval of the Company's 2026 Equity Incentive Plan. at the 2026-05-14 meeting.","evidence_excerpt":"Proposal 4 Approval of the Company's 2026 Equity Incentive Plan. Votes For Votes Against Votes Abstained Broker Non-Vote 18,693,758 3,513,983 48,202 2,323,053","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1674930/000119312526224147/0001193125-26-224147-index.htm","confidence":0.99,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-05-14"}],"fact_type":"shareholder_vote"},{"claim_id":"6fec72942ded3517d12167d24b039020ac0ee4de","claim":"Fulgent Genetics, Inc. shareholders approved Election of the following nominees as directors of the Company, each to serve until the 2027 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified. at the 2026-05-14 meeting.","evidence_excerpt":"Proposal 1 Election of the following nominees as directors of the Company, each to serve until the 2027 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified. Votes For Votes Withheld Broker Non-Vote Ming Hsieh 21,979,668 276,275 2,323,053 Linda Dong 16,836,781 5,419,162 2,323,053 Michael Nohaile, Ph.D. 17,258,629 4,997,314 2,323,053 Regina Groves 16,240,666 6,015,277 2,323,053","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1674930/000119312526224147/0001193125-26-224147-index.htm","confidence":0.99,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-05-14"}],"fact_type":"shareholder_vote"},{"claim_id":"9e8190477285c42c0e60362ab4ff13f4ec8e67ff","claim":"Fulgent Genetics, Inc. shareholders approved Ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. at the 2026-05-14 meeting.","evidence_excerpt":"Proposal 2 Ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. Votes For Votes Against Votes Abstained Broker Non-Vote 24,470,414 87,192 21,390 —","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1674930/000119312526224147/0001193125-26-224147-index.htm","confidence":0.99,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-05-14"}],"fact_type":"shareholder_vote"},{"claim_id":"e2ea1150e0c1e2b42b9d8d709891698e39024957","claim":"Fulgent Genetics, Inc. shareholders approved Approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers. at the 2026-05-14 meeting.","evidence_excerpt":"Proposal 3 Approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers. Votes For Votes Against Votes Abstained Broker Non-Vote 19,800,226 2,410,239 45,478 2,323,053","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1674930/000119312526224147/0001193125-26-224147-index.htm","confidence":0.99,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-05-14"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}